Efficacy and Tolerance of Honey-impregnated Dressings in the Local Management of Pressure Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-20

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to document the effectiveness of a honey-based medical device (Hyalumel) in the management of pressure ulcers. The effectiveness of the medical device will be judged according to the evolution of the surface of the wound at the end of 12 weeks of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Value of Using a Honey Dressing Compared to the Use of a Standard Dressing on the Toe Amputation Wound in the Diabetic Patient

NCT03934281

Diabete Mellitus Amputation Amputation Wound +1 more

COMPLETED NA

Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers

NCT02689310

Pressure Ulcers

WITHDRAWN PHASE4

Use of Honey for Pressure Ulcers in Critically Ill Children

NCT03391310

Bed Sore Pressure Ulcer Pressure Sore +1 more

COMPLETED NA

Prevention of Pressure Ulcer on the Sacrum

NCT03900455

Pressure Ulcer Risk

COMPLETED NA

Medical Honey for Wound Treatment in Intensive Care. (MICARéa) Randomized, Controlled, Single-center Pilot Study.

NCT06150326

Wound Heal Critical Illness

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The secondary objectives of this study are to compare the following items between the two arms of the study:

A. The evolution of skin microbiota in the wound B. The evolution of the surface and the depth of the wound during follow-up C. The healing process D. Patient and caretaker acceptability

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pressure Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MELECTIS G

In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.

Intervention: Usual care Intervention: MELECTIS G

Group Type EXPERIMENTAL

MELECTIS G

Intervention Type DEVICE

The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.

Usual care

Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).

Intervention: Usual care

Group Type ACTIVE_COMPARATOR

MELECTIS G

Intervention Type DEVICE

The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.

Usual care

Intervention Type PROCEDURE

Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MELECTIS G

The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.

Intervention Type DEVICE

Usual care

Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Information provided on the implementation of the study, its objectives, constraints and patient rights
* The patient, or his/her legal guardian, must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* The patient is available for 12 weeks of follow-up
* Presence of one or more pressure ulcers at stages 2, 3 or 4 according to the European Pressure Ulcer Advisory Panel - National Pressure Ulcer Advisory Panel (EPUAP-NPUAP) classification
* Wound whose surface is between 1 cm\^2 and 15 cm\^2
* Wound present for more than 6 weeks
* Patient whose wound requires a modern dressing (that is to say, a bandage that is neither tulle nor gauze) without bactericidal agents or antibiotics
* No antibiotics for at least 7 days prior to inclusion (after inclusion, the patient can be treated with antibiotics if necessary, regardless of the indications)

Exclusion Criteria

* Patient participating in or having participated in another interventional study in the previous 3 months or currently in a patient exclusion period determined by a previous study.
* Patient under judicial protection
* Failure to correctly inform the patient or his/her legal representative
* Patient (or his/her legal guardian) refusal to sign the consent
* The patient is pregnant, parturient, or breastfeeding
* Contraindications (or incompatible combination therapy) for a necessary treatment in this study
* Patient with an allergy to honey or propolis
* The patient's general condition suggests study exclusion before twelve weeks of follow-up
* Antibiotics received within 7 days prior to inclusion
* Active neoplastic lesion treated with radiation or chemotherapy
* Immunosuppressive therapy or other treatment which, in the judgment of the investigator, may interfere with the healing process
* Surgery planned within twelve weeks of inclusion
* Stage 1 wound according to the EPUAP-NPUAP classification
* Amputation wound
* Wound related to a surgical treatment or for which an act of revascularization is envisaged within twelve weeks of inclusion
* Malignant wound

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No